BlackRock Institutional Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

BlackRock Institutional Trust’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10.7M	Buy	516,855 +12,334	+2%	+$207K	﹤0.01%	2360
2016 Q3	$8.18M	Sell	504,521 -10,418	-2%	-$151K	﹤0.01%	2455
2016 Q2	$7M	Buy	514,939 +22,532	+5%	+$398K	﹤0.01%	2504
2016 Q1	$8.6M	Buy	492,407 +53,008	+12%	+$1.08M	﹤0.01%	2361
2015 Q4	$15M	Buy	439,399 +147,599	+51%	+$5.12M	﹤0.01%	2057
2015 Q3	$8.68M	Buy	291,800 +88,293	+43%	+$2.68M	﹤0.01%	2387
2015 Q2	$6.51M	Buy	203,507 +104,776	+106%	+$2.69M	﹤0.01%	2651
2015 Q1	$2.05M	Buy	98,731 +4,109	+4%	+$71K	﹤0.01%	3102
2014 Q4	$1.6M	Buy	94,622 +484	+0.5%	+$8.45K	﹤0.01%	3203
2014 Q3	$1.82M	Sell	94,138 -26,562	-22%	-$692K	﹤0.01%	3118
2014 Q2	$4.1M	Sell	120,700 -30,893	-20%	-$968K	﹤0.01%	2872
2014 Q1	$4.78M	Buy	+151,593	New	+$4.74M	﹤0.01%	2805

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock Institutional Trust's RVNC Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Revance Therapeutics, Inc. (RVNC) stake by 2.4% in Q4 2016, buying an estimated $207K and bringing the position to 516,855 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2360.

BlackRock Institutional Trust first reported a position in RVNC in Q1 2014 and has held it in 12 quarters since. The position peaked at $15M in Q4 2015. 81 funds tracked by Wall St. Rank hold RVNC as of Q4 2016.

BlackRock Institutional Trust held 516,855 shares of Revance Therapeutics, Inc. worth $10.7M as of Q4 2016.
BlackRock Institutional Trust bought 12,334 Revance Therapeutics, Inc. shares in Q4 2016, an estimated $207K.
Revance Therapeutics, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2360 holding.
BlackRock Institutional Trust first reported a position in Revance Therapeutics, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Revance Therapeutics, Inc. position peaked at $15M in Q4 2015.
81 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.